AZ HB4036

Prohibits the sale or distribution of compounded weight loss drugs (GIP receptor or GLP-1 receptor agonists) in Arizona unless the compounder meets strict bulk drug substance sourcing requirements, including using pharmaceutical-grade substances from FDA-registered and inspected facilities not subject to import alerts.

Requires compounders to conduct quality control testing of bulk drug substances before use and finished products before release, documenting identity, content, and any impurities exceeding 0.1%.

Mandates that manufacturers and wholesalers provide written verification of pharmaceutical grade status and certificates of analysis when selling bulk drug substances for compounding in Arizona.

Imposes advertising restrictions requiring compounded medication ads to include potential side effects, risk information, and a clear statement that the product is not FDA-approved for safety or efficacy.

Establishes penalties of $1,000 per dose for violations, plus potential license suspension or revocation, and grants the Arizona Board of Pharmacy inspection authority over compounders and their suppliers.